Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Meningeal Carcinomatosis 1

Interventions

pembrolizumab 602Cyclophosphamide 545Magnetic Resonance Spectroscopy 524Radiotherapy 513Specimen Handling 506Nivolumab 412Cisplatin 380Carboplatin 368Biopsy 306Blood Specimen Collection 302Radiosurgery 290Paclitaxel 280Surveys and Questionnaires 270Gemcitabine 270Standard of Care 267Drug Therapy 263Dexamethasone 263fludarabine 262Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 198Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 184Doxorubicin 179Etoposide 176atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Deferoxamine × 1 year × Clear all
NCT05184816 2026-03-27

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
35 enrolled
CNS

Recurrence, Meningeal Carcinomatosis

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Sun Yat-sen University

Phase 2 Terminated
25 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡